1
|
Ryba A, Özdemir Z, Nissimov N, Hönikl L, Neidert N, Jakobs M, Kalasauskas D, Krigers A, Thomé C, Freyschlag CF, Ringel F, Unterberg A, Dao Trong P, Beck J, Heiland DH, Meyer B, Vajkoczy P, Onken J, Stummer W, Suero Molina E, Gempt J, Westphal M, Schüller U, Mohme M. Insights from a Multicenter Study on Adult H3 K27M-Mutated Glioma: Surgical Resection's Limited Influence on Overall Survival, ATRX as Molecular Prognosticator. Neuro Oncol 2024:noae061. [PMID: 38507506 DOI: 10.1093/neuonc/noae061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Indexed: 03/22/2024] Open
Abstract
BACKGROUND H3 K27M-mutated gliomas were first described as a new grade 4 entity in the 2016 WHO classification. Current studies have focused on its typical appearance in children and young adults, increasing the need to better understand the prognostic factors and impact of surgery on adults. Here, we report a multicentric study of this entity in adults. METHODS We included molecularly confirmed H3 K27M-mutated glioma cases in patients >18 years diagnosed between 2016 and 2022. Clinical, radiological, and surgical features were analyzed. Univariate and multivariate analyses were performed to identify prognostic factors. RESULTS Among 70 patients with a mean age of 36.1 years, the median overall survival (OS) was 13.6 + 14 months. Gross-total resection was achieved in 14.3% of patients, whereas 30% had a subtotal resection and 54.3% a biopsy.Tumors located in telencephalon/diencephalon/myelencephalon were associated with a poorer OS, while a location in the mesencephalon/metencephalon showed a significantly longer OS (8.7 vs. 25.0 months, p=0.007). Preoperative Karnofsky Performance Score (KPS) < 80 showed a reduced OS (4.2 vs. 18 months, p=0.02). Furthermore, ATRX loss, found in 25.7%, was independently associated with an increased OS (31 vs. 8.3 months, p=0.0029). Notably, patients undergoing resection showed no survival benefit over biopsy (12 vs. 11 months, p=0.4006). CONCLUSION The present study describes surgical features of H3 K27M-mutated glioma in adulthood in a large multicentric study. Our data reveal that ATRX status, location and KPS significantly impact OS in H3 K27M-mutated glioma. Importantly, our dataset indicates that resection does not offer a survival advantage over biopsy.
Collapse
Affiliation(s)
- A Ryba
- Department of Neurosurgery, Medical Center Hamburg-Eppendorf, Germany
| | - Z Özdemir
- Department of Neurosurgery, University Hospital of Münster, Germany
| | - N Nissimov
- Department of Neurosurgery, Charité University Hospital Berlin, Germany
| | - L Hönikl
- Department of Neurosurgery, Technical University Munich, Germany
| | - N Neidert
- Department of Neurosurgery, Medical Center - University of Freiburg, Germany
| | - M Jakobs
- Department of Neurosurgery, Heidelberg University Hospital, Germany
- Department of Neurosurgery, Division of Stereotactic Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany
- Heidelberg University, Medical Faculty, Heidelberg, Germany
| | - D Kalasauskas
- Department of Neurosurgery, University Medical Center Mainz, Germany
| | - A Krigers
- Department of Neurosurgery, Medical University of Innsbruck, Austria
| | - C Thomé
- Department of Neurosurgery, Medical University of Innsbruck, Austria
| | - C F Freyschlag
- Department of Neurosurgery, Medical University of Innsbruck, Austria
| | - F Ringel
- Department of Neurosurgery, University Medical Center Mainz, Germany
| | - A Unterberg
- Department of Neurosurgery, Heidelberg University Hospital, Germany
- Heidelberg University, Medical Faculty, Heidelberg, Germany
| | - P Dao Trong
- Department of Neurosurgery, Heidelberg University Hospital, Germany
- Heidelberg University, Medical Faculty, Heidelberg, Germany
| | - J Beck
- Department of Neurosurgery, Medical Center - University of Freiburg, Germany
| | - D H Heiland
- Department of Neurosurgery, Medical Center - University of Freiburg, Germany
| | - B Meyer
- Department of Neurosurgery, Technical University Munich, Germany
| | - P Vajkoczy
- Department of Neurosurgery, Charité University Hospital Berlin, Germany
| | - J Onken
- Department of Neurosurgery, Charité University Hospital Berlin, Germany
| | - W Stummer
- Department of Neurosurgery, University Hospital of Münster, Germany
| | - E Suero Molina
- Department of Neurosurgery, University Hospital of Münster, Germany
| | - J Gempt
- Department of Neurosurgery, Medical Center Hamburg-Eppendorf, Germany
| | - M Westphal
- Department of Neurosurgery, Medical Center Hamburg-Eppendorf, Germany
| | - U Schüller
- Institute of Neuropathology, Medical Center Hamburg-Eppendorf, Germany
- Department of Pediatric Hematology and Oncology, Medical Center Hamburg-Eppendorf, Germany
- Research Institute Children's Cancer Center Hamburg, Germany
| | - M Mohme
- Department of Neurosurgery, Medical Center Hamburg-Eppendorf, Germany
| |
Collapse
|
2
|
Belasen AM, Peek RA, Adams AJ, Russell ID, De León ME, Adams MJ, Bettaso J, Breedveld KGH, Catenazzi A, Dillingham CP, Grear DA, Halstead BJ, Johnson PG, Kleeman PM, Koo MS, Koppl CW, Lauder JD, Padgett-Flohr G, Piovia-Scott J, Pope KL, Vredenburg V, Westphal M, Wiseman K, Kupferberg SJ. Chytrid infections exhibit historical spread and contemporary seasonality in a declining stream-breeding frog. R Soc Open Sci 2024; 11:231270. [PMID: 38298390 PMCID: PMC10827429 DOI: 10.1098/rsos.231270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/26/2023] [Accepted: 12/18/2023] [Indexed: 02/02/2024]
Abstract
Species with extensive geographical ranges pose special challenges to assessing drivers of wildlife disease, necessitating collaborative and large-scale analyses. The imperilled foothill yellow-legged frog (Rana boylii) inhabits a wide geographical range and variable conditions in rivers of California and Oregon (USA), and is considered threatened by the pathogen Batrachochytrium dendrobatidis (Bd). To assess drivers of Bd infections over time and space, we compiled over 2000 datapoints from R. boylii museum specimens (collected 1897-2005) and field samples (2005-2021) spanning 9° of latitude. We observed a south-to-north spread of Bd detections beginning in the 1940s and increase in prevalence from the 1940s to 1970s, coinciding with extirpation from southern latitudes. We detected eight high-prevalence geographical clusters through time that span the species' geographical range. Field-sampled male R. boylii exhibited the highest prevalence, and juveniles sampled in autumn exhibited the highest loads. Bd infection risk was highest in lower elevation rain-dominated watersheds, and with cool temperatures and low stream-flow conditions at the end of the dry season. Through a holistic assessment of relationships between infection risk, geographical context and time, we identify the locations and time periods where Bd mitigation and monitoring will be critical for conservation of this imperilled species.
Collapse
Affiliation(s)
- A. M. Belasen
- Department of Integrative Biology, University of Texas at Austin, Austin, TX, USA
- Department of Ecology and Evolutionary Biology, Cornell University, Ithaca, NY, USA
| | - R. A. Peek
- California Department of Fish and Wildlife, West Sacramento, CA, USA
| | - A. J. Adams
- Earth Research Institute, University of California, Santa Barbara, CA, USA
| | - I. D. Russell
- Department of Ecology, Evolution, and Marine Biology, University of California, Santa Barbara, CA, USA
| | - M. E. De León
- Genome Center, University of California, Davis, CA, USA
| | - M. J. Adams
- U.S. Geological Survey, Forest and Rangeland Ecosystem Science Center, Corvallis, OR, USA
| | - J. Bettaso
- Six Rivers National Forest, Lower Trinity Ranger District, USDA Forest Service, P.O. Box 68, Willow Creek, CA, USA
| | | | - A. Catenazzi
- Department of Biological Sciences, Florida International University, Miami, FL, USA
| | | | - D. A. Grear
- U.S. Geological Survey, National Wildlife Health Center, Madison, WI, USA
| | - B. J. Halstead
- Point Reyes Field Station, U.S. Geological Survey, Western Ecological Research Center, Point Reyes Station, CA, USA
| | - P. G. Johnson
- Pinnacles National Park, National Park Service, Paicines, CA, USA
| | - P. M. Kleeman
- Point Reyes Field Station, U.S. Geological Survey, Western Ecological Research Center, Point Reyes Station, CA, USA
| | - M. S. Koo
- Museum of Vertebrate Zoology, University of California, Berkeley, CA
| | - C. W. Koppl
- Plumas National Forest, USDA Forest Service, Quincy, CA, USA
| | | | | | - J. Piovia-Scott
- School of Biological Sciences, Washington State University, Vancouver, WA, USA
| | - K. L. Pope
- Pacific Southwest Research Station, USDA Forest Service, Arcata, CA, USA
| | - V. Vredenburg
- Department of Biology, San Francisco State University, San Francisco, CA, USA
| | - M. Westphal
- Central Coast Field Office, United States Bureau of Land Management, Marina, CA, USA
| | - K. Wiseman
- Department of Herpetology, California Academy of Sciences, San Francisco, CA, USA
| | - S. J. Kupferberg
- Department of Integrative Biology, University of California, Berkeley, CA, USA
| |
Collapse
|
3
|
Takei H, Saito N, Okamoto T, Watanabe K, Westphal M, Tomioka R, Gölzhäuser A. Mass producible, robust SERS substrates based on metal film on nanosphere (MFON) on an adhesive substrate for detection of surface-adsorbed molecules and their evaluation by helium ion microscopy. Analyst 2023. [PMID: 37212023 DOI: 10.1039/d3an00272a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
We have developed a SERS stamp that can be pressed directly onto a solid surface for characterization of surface-adsorbed target molecules. The stamp was fabricated by transfer of a dense monolayer of SiO2 nanospheres from a glass surface onto a piece of adhesive tape and subsequent evaporation of silver. The performance of the resulting SERS stamps was evaluated by their exposure to methyl mercaptan vapor, and immersion in rhodamine 6G and ferbam solutions. It was found that beside the nanosphere diameter and metal deposition thickness, the extent of burial of the nanospheres into the adhesive tape, dictated by the pressure during the nanosphere transfer process, had a significant effect. We carried out FDTD calculations of the near field. Models are based on morphological information obtained from helium ion microscopy, which can provide high-resolution images of poor electrical conductors such as our SERS stamp. While one of our main eventual goals is detection of pesticides on agricultural produce, we have begun to take a careful step by testing our SERS stamp on better characterized surfaces such as a porous gel surface, having been immersed in fungicides such as ferbam. We also present our preliminary results with ferbam on oranges. It is expected that our well-characterized SERS stamp will play a role in shedding light on the poorly studied transfer process of target molecules onto a SERS surface as well as serving as a new SERS platform.
Collapse
Affiliation(s)
- H Takei
- Faculty of Life Sciences, Toyo University, Gunma 374-0193, Japan.
- Bio-Nano Electronics Research Centre, Toyo University, Saitama 350-8585, Japan
| | - N Saito
- Graduate School of Life Sciences, Toyo University, Gunma 374-0193, Japan
| | | | - K Watanabe
- Graduate School of Life Sciences, Toyo University, Gunma 374-0193, Japan
| | - M Westphal
- Faculty of Physics, Physics of Supramolecular Systems, University of Bielefeld, 33615, Bielefeld, Germany
| | - R Tomioka
- Graduate School of Life Sciences, Toyo University, Gunma 374-0193, Japan
| | - A Gölzhäuser
- Faculty of Physics, Physics of Supramolecular Systems, University of Bielefeld, 33615, Bielefeld, Germany
| |
Collapse
|
4
|
Bamidele AO, Sagstetter MR, Hirsova P, Ramos GP, Klatt E, Westphal M, Faubion W. Interleukin 21‐induced Mitochondrial Dysfunction Drives Regulatory T Cell Inflammatory Response during Intestinal Inflammation. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r5953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | - Petra Hirsova
- Gastroenterology and HepatologyMayo ClinicRochesterMN
| | | | | | | | | |
Collapse
|
5
|
Pontones M, Höfener H, Kock F, Schwen L, Westphal M, Dickel N, Kunz M, Metzler M. Comprehensive bone marrow analysis integrating deep learning-based
pattern discovery (BMDeep). KLINISCHE PADIATRIE 2022. [DOI: 10.1055/s-0042-1748749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | | | - F Kock
- Fraunhofer MEVIS, Germany
| | | | | | | | | | - M Metzler
- Universitätsklinikum Erlangen, Germany
| |
Collapse
|
6
|
Bamidele A, Sagstetter M, Hirsova P, Ramos GP, Westphal M, Faubion WA. Metabolic Dysfunction Governs Regulatory T Cell Inflammatory Response during Inflammatory Bowel Disease. The Journal of Immunology 2022. [DOI: 10.4049/jimmunol.208.supp.108.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Abstract
Background
Significant proportion of inflammatory bowel disease (IBD) patients respond inconsistently to therapies, underscoring disease complexity. Interleukin 21 (IL21) is highly expressed during IBD. In addition to T helper (Th) cells, inflammatory regulatory T cells (Tregs) have been linked to refractory IBD. Thus, we explored the metabolic role of IL21 in inducing Treg dysfunction and IBD.
Methods
Human Tregs and Th cells were subjected to transcriptional profiling and metabolic phenotyping. Colitis was induced in Rag1−/− mice by naïve CD4 T cell adoptive transfer.
Results
IL21 stimulation of human Tregs induced glycolysis and OXPHOS. In agreement, IL21 enhanced the expression of genes associated with glycolysis, anabolism, and OXPHOS, leading to inflammatory cytokine production. Mechanistically, we found disruption to mitochondrial integrity with concomitant activation of glycogen synthase kinase 3 (GSK3) β, a kinase known to prevent mitochondrial pyruvate metabolism. IL21-induced GSK3β activation was accompanied by pyruvate and lactate buildup. Notably, GSK3 inhibition or supplementation with membrane-permeable methyl pyruvate abrogated metabolic wiring of and inflammatory responses by IL21-stimulated Tregs and effector Th cells. These results suggest that impaired mitochondrial pyruvate metabolism is a feature of inflammatory CD4 T cells. Lastly, GSK3 inhibition prevented pathogenic CD4 T cell-induced colitis in mice, as evidenced by reduced Mouse Colon Histology Index and serum inflammatory cytokines.
Conclusions
IL21 engages Tregs in a hypermetabolic state that augments inflammatory cytokine production. Therefore, desensitizing CD4 T cells to IL21 may also augment Treg function during IBD.
Supported by NIDDK award K01DK124358, the Center for Cell Signaling in Gastroenterology (P30DK084567), and the Mayo Clinic Center for Biomedical Discovery.
Collapse
Affiliation(s)
| | | | - Petra Hirsova
- 1Gastroenterology & Hepatology, Mayo Clinic Rochester
| | | | | | | |
Collapse
|
7
|
Schliffke S, Maire C, Holz M, Bokemeyer C, Westphal M, Lamszus K, Mohme M. P16.06 Immunophenotyping of tumor-infiltrating T cells in primary CNS lymphoma. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Primary CNS lymphoma represents a malignant disease with dismal prognosis. Standard of care is high dose chemotherapy and radiation. However, this combination cannot be applied to the elderly and fragile population. Immunotherapy holds great promise to be effective in these patients. This study therefore aims to explore the phenotype of tumor-infiltrating lymphocytes (TIL) in order to analyze the potential for immune checkpoint inhibition.
MATERIAL AND METHODS
We performed ex vivo multicolor flow-cytometry on surgical specimens of nine patients with intracerebral lymphoma, including seven with primary CNS lymphoma after isolation of TILs following standard protocols. Data was analyzed using a Fortessa LSR flow cytometer and Diva software. The study was approved by the local ethics committee (PV4904).
RESULTS
Our ex vivo phenotyping demonstrated a predominant infiltration of CD8+ T cells, which outnumber CD4+ T cells by a ratio of 2:1 (p<0.01). Regulatory T cells (Tregs) were not increased in the tumor microenvironment and the NK cell frequency was reduced compared to the peripheral blood. While CD4+ T helper cells displayed significantly increased surface expression of multiple activation and checkpoint markers, including TIGIT, PD-1, Tim3 and CD57, cytotoxic CD8+ T cells predominantly expressed only TIGIT and PD-1. On average 70% and 80% of CD8+ T cells expressed PD-1 and TIGIT, respectively, compared to 35% and 60% of PD-1 and TIGIT on CD4+ T cells (p<0.05). CD8+ T cells furthermore showed an increased expression of CD39 and a simultaneous downregulation of CD73, both ectoenzyms involved in the modulation of intratumoral ATP, thereby indicating a metabolic immune modulation by the tumor.
CONCLUSION
Taken together, our study demonstrates a strong infiltration of cytotoxic CD8+ T cells into cerebral lymphoma, which potentially can be disinhibited using checkpoint immunotherapy. Our profiling suggests that PD-1 and TIGIT present appealing targets for such kind of immune disinhibition.
Collapse
Affiliation(s)
- S Schliffke
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - C Maire
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Holz
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - C Bokemeyer
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Westphal
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - K Lamszus
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Mohme
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
8
|
Mohme M, Maire C, Rünger A, Glau L, Tolosa E, Westphal M, Lamszus K. P16.03 Cerebral gliom alters the peripheral CD4+ T helper cell phenotype. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
BACKGROUND
Cancer is a systemic disease. Due to the exceedingly rare occurrence of metastasis of cerebral glioma, systemic alterations have, however, not been considered to play a major role in disease progression of glioma. CD4+ T helper (TH) cells orchestrate the adaptive immune response in an antigen-specific, cytokine mediated manner. The aim of our study was to investigate how far cerebral glioma impacts the systemic CD4+ immune repertoire.
MATERIAL AND METHODS
We performed flow-cytometry analysis of the peripheral blood CD4+ TH cell phenotype and cytokine production in 100 patients with IDHwt, 30 IDHmut and 16 IDHmut 1p19q co-deleted gliomas in comparison with age-matched healthy donors (HD). Data was analyzed using a Fortessa LSR and Diva software. Multiparameter analyses were performed using UMAP and SpadeVizR trees. The study was approved by the ethics committee (PV4904).
RESULTS
We found a significant skewing of the peripheral immunophenotype in IDHwt glioma patients, showing a TH1 expansion and reduced numbers of T follicular helper cells (TFH), TH1* and mucosa associated invariant T (MAIT) cells (p<0.001), while TH2 and TH17 percentages remained stable compared to IDHmut and HD. Although TH1 cells were dominant in IDHwt patients (p<0.01), intracellular cytokine staining showed a reduction of IFNγ and TNFα production after in vitro stimulation, while IL-4 was significantly increased compared to HD (p<0.05). No alterations between all groups were observed in IL-2, IL-10 or IL-17 production. Profiling of metabolic surface markers further revealed increased expression of GLUT1 on CD4+ T cells in IDHwt patients, indicating an activated CD4+ repertoire compared to HD.
CONCLUSION
Taken together, our results show a CD4+ TH cell type specific skewing of the peripheral immune repertoire in patients with IDHwt gliomas. Our data highlights the importance of considering malignant glioma as a disease with profound systemic effects fundamentally altering the immune repertoire in affected patients.
Collapse
Affiliation(s)
- M Mohme
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - C Maire
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Rünger
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - L Glau
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - E Tolosa
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Westphal
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - K Lamszus
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
9
|
Weller M, Gramatzki D, Felsberg J, Hentschel B, Wolter M, Schackert G, Westphal M, Regli L, Thon N, Tatagiba M, Wick W, Schlegel U, Krex D, Roth P, Rushing E, Pietsch T, von Deimling A, Sabel M, Loeffler M, Reifenberger G. 360O Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link? Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
10
|
Seystahl K, Hentschel B, Loew S, Gramatzki D, Felsberg J, Herrlinger U, Westphal M, Schackert G, Thon N, Schlegel U, Tatagiba M, Pietsch T, Reifenberger G, Löffler M, Wick W, Weller M. P14.108 Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
The use of alkylating chemotherapy versus bevacizumab for recurrent glioblastoma remains controversial. Here we tested the hypothesis that the activity of alkylators, but not that of bevacizumab, would be associated with the O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status
PATIENTS AND METHODS
We analyzed a cohort of patients treated at centers of the German Glioma Network or the University Hospital Zurich with alkylating agent-based chemotherapy (n=260) or bevacizumab without or with irinotecan (n=84) for first recurrence of glioblastoma. Outcome was stratified for MGMT status and cross-over to bevacizumab or alkylators at further tumor progression.
RESULTS
Median post-recurrence survival-1 (PRS-1) for patients receiving alkylating agent chemotherapy at first recurrence was longer than for patients receiving bevacizumab (11.1 versus 7.4 months, p<0.001). The use of alkylating agents was associated with longer PRS-1 for patients with a methylated versus an unmethylated MGMT promoter (p=0.017). For patients receiving bevacizumab, PRS-1 was not different with or without MGMT promoter methylation. PRS-1 was longer in the group receiving alkylating chemotherapy compared to bevacizumab for patients with a methylated (p<0.001) or unmethylated MGMT promoter (p=0.034). For patients with alkylators at first recurrence receiving bevacizumab at any further recurrence, PRS-1 was longer than in patients receiving bevacizumab first and alkylators thereafter (p=0.002).
CONCLUSION
This study confirms limited value of bevacizumab in recurrent glioblastoma independent of MGMT status. Alkylating agents have activity in recurrent glioblastoma, especially in the context of a methylated MGMT promoter.
Collapse
Affiliation(s)
- K Seystahl
- Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland
| | - B Hentschel
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - S Loew
- Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
| | - D Gramatzki
- Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland
| | - J Felsberg
- Department of Neuropathology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - U Herrlinger
- Department of Neurology, Division of Clinical Neuro-oncology, University of Bonn Medical Center, Bonn, Germany
| | - M Westphal
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Hamburg, Germany
| | - G Schackert
- Department of Neurosurgery, Carl Gustav Carus University Hospital, Technical University of Dresden, Dresden, Germany
| | - N Thon
- Department of Neurosurgery, University of Munich LMU, Munich, Germany
| | - U Schlegel
- Department of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr-Universität Bochum, Bochum, Germany
| | - M Tatagiba
- Department of Neurosurgery, Eberhard-Karls-University, University Hospital Tübingen, Tübingen, Germany
| | - T Pietsch
- Department of Neuropathology, University of Bonn, Bonn, Germany
| | - G Reifenberger
- Department of Neuropathology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - M Löffler
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - W Wick
- Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
| | - M Weller
- Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland
| |
Collapse
|
11
|
Gramatzki D, Felsberg J, Bähr O, Hentschel B, Westphal M, Schackert G, Tonn JC, Herrlinger U, Löffler M, Pietsch T, Steinbach J, Reifenberger G, Roth P, Weller M. OS2.2 Chemotherapy for spinal gliomas in adults. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Chemotherapy is a treatment option in patients diagnosed with anaplastic gliomas or glioblastomas of the spinal cord, or with recurrent lower graded WHO spinal gliomas that are no longer amenable to local treatment. The low incidence of spinal cord gliomas, particularly in adults, limits the ability to perform clinical trials. The role of chemotherapy in these tumors has remained unclear.
MATERIAL AND METHODS
We performed a retrospective study of 22 patients diagnosed with spinal gliomas who were treated with chemotherapy at any time during the disease course. Benefit from chemotherapy was estimated by applying Response assessment in neuro-oncology criteria. Data on radiotherapy, as well as the number of neurosurgical interventions were taken into consideration.
RESULTS
Most patients were diagnosed with astrocytoma WHO grade I-IV (N=14), the remaining patients were diagnosed with ependymoma (N=8). Median follow-up from start of chemotherapy was 92 months (95% CI, 72.6–111.4). The O6-methylguanyl-DNA-methyltransferase(MGMT)promoter methylation status was available in tumors of 12 patients: 9 tumors (75%) had an unmethylated MGMTpromoter. More than 50% of the patients had more than one neurosurgical intervention. After prior surgery 10 patients in the first-line setting had chemotherapy combined with radiotherapy, while 3 patients received chemotherapy only. The remaining 9 patients had initially received radiation therapy and chemotherapy was given at time of recurrence. In patients diagnosed with astrocytoma mainly temozolomide (TMZ) was applied (N=10), while one patient received CCNU and three patients had combination chemotherapy. Patients diagnosed with ependymoma had hydroxyurea (N=1), CCNU (N=1), TMZ (N=3) or combination chemotherapy (N=3). In the group of patients who had chemotherapy combined with radiation, response rates were as follows: anaplastic astrocytoma 3 stable diseases (SD), glioblastoma 1 complete response (CR) and 1 SD, and anaplastic ependymoma 1 SD. After chemotherapy in the group of patients previously irradiated, the following response rates were observed: 1 SD in pilocytic astrocytoma, 1 SD in diffuse astrocytoma, 3 SD in myxopapillary ependymoma, and 2 SD and 1 partial response (PR) in anaplastic ependymoma. All other patients experienced progressive disease. There was no indication for a favorable prognostic role ofMGMTpromoter methylation.
CONCLUSION
Spinal cord gliomas represent a heterogeneous group of tumors. Survival outcomes in response to chemotherapy in adult spinal glioma patients vary substantially, but individual patients appear to derive benefit from chemotherapy.
Collapse
Affiliation(s)
- D Gramatzki
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - J Felsberg
- Department of Neuropathology, Heinrich-Heine-University, Düsseldorf, Germany
| | - O Bähr
- Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital, Frankfurt, Germany
| | - B Hentschel
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - M Westphal
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - G Schackert
- Department of Neurosurgery, Technical University Dresden, Dresden, Germany
| | - J C Tonn
- Department of Neurosurgery, Ludwig Maximilian University Munich, Munich, Germany
| | - U Herrlinger
- Division of Clinical Neurooncology, University Hospital Bonn, Bonn, Germany
| | - M Löffler
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - T Pietsch
- Department of Neuropathology, University Hospital Bonn, Bonn, Germany
| | - J Steinbach
- Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital, Frankfurt, Germany
| | - G Reifenberger
- Department of Neuropathology, Heinrich-Heine-University, Düsseldorf, Germany
| | - P Roth
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - M Weller
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
12
|
Huckhagel T, Westphal M, Hamel W. FV 22 Adverse events requiring surgical intervention during long-term Spinal Cord Stimulation for chronic pain syndromes_a retrospective single-center analysis. Clin Neurophysiol 2019. [DOI: 10.1016/j.clinph.2019.04.632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Hidding U, Gulberti A, Pflug C, Choe C, Horn A, Prilop L, Braaß H, Fründt O, Buhmann C, Weiss D, Westphal M, Engel A, Gerloff C, Köppen J, Hamel W, Moll C, Pötter-Nerger M. Modulation of specific components of sleep disturbances by simultaneous subthalamic and nigral stimulation in Parkinson's disease. Parkinsonism Relat Disord 2019; 62:141-147. [DOI: 10.1016/j.parkreldis.2018.12.026] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2018] [Revised: 11/26/2018] [Accepted: 12/22/2018] [Indexed: 10/27/2022]
|
14
|
Maybauer DM, Talke PO, Westphal M, Maybauer MO, Traber LD, Enkhbaatar P, Morita N, Traber DL. Positive End-expiratory Pressure Ventilation Increases Extravascular Lung Water Due to a Decrease in Lung Lymph Flow. Anaesth Intensive Care 2019; 34:329-33. [PMID: 16802485 DOI: 10.1177/0310057x0603400307] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Positive end-expiratory pressure (PEEP) is used to improve gas exchange, increase functional residual capacity, recruit air spaces, and decrease pulmonary shunt in patients suffering from respiratory failure. The effect of PEEP on extravascular lung water (EVLW), however, is still not fully understood. This study was designed as a prospective laboratory experiment to evaluate the effects of PEEP on EVLW and pulmonary lymph flow (QL) under physiologic conditions. Twelve adult sheep were operatively prepared to measure haemodynamics of the systemic and pulmonary circulation, and to assess EVLW. In addition, the lung lymphatic duct was cannulated and a tracheostomy performed. The animals were then mechanically ventilated in the awake-state without end-expiratory pressure (PEEP 0). After a two-hour baseline period, PEEP was increased to 10 cmH2O for the duration of two hours, and then reduced back to 0 cmH2O. Cardiopulmonary variables, QL, and arterial blood gases were recorded intermittently; EVLW was determined two hours after each change in PEEP. The increase in PEEP resulted in a decrease in QL (7±1 vs 5±1 ml/h) and an increase in EVLW (498±40 vs 630±58 ml; P<0.05 each) without affecting cardiac output. As PEEP was decreased back to baseline, QL increased significantly (5±1 vs 10±2 ml/h), whereas EVLW returned back to baseline. This study suggests that institution of PEEP produces a reversible increase in EVLW that is linked to a decrease in QL.
Collapse
Affiliation(s)
- D M Maybauer
- Department of Anaesthesiology, Investigational Intensive Care Unit, The University of Texas Medical Branch, and Shriners Burns Hospital for Children at Galveston, USA
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Herold-Mende CC, Rapp C, Jungk C, Sahm F, Lamszus K, Ketter R, Löhr M, Senft C, Westphal M, von Deimling A, Unterberg A, Simon M. P04.79 Cytotoxic T cells and their activation status are independent prognostic markers in meningiomas. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- C C Herold-Mende
- Department of Neurosurgery, University of Heidelberg, Germany, Heidelberg, Germany
| | - C Rapp
- Department of Neurosurgery, University of Heidelberg, Germany, Heidelberg, Germany
| | - C Jungk
- Department of Neurosurgery, University of Heidelberg, Germany, Heidelberg, Germany
| | - F Sahm
- Department of Neuropathology, University of Heidelberg, Germany, Heidelberg, Germany
| | - K Lamszus
- Department of Neurosurgery, University of Hamburg, Germany, Hamburg, Germany
| | - R Ketter
- Department of Neurosurgery, University of Homburg, Germany, Homburg, Germany
| | - M Löhr
- Department of Neurosurgery, University of Würzburg, Germany, Würzburg, Germany
| | - C Senft
- Department of Neurosurgery, University of Frankfurt, Germany, Frankfurt, Germany
| | - M Westphal
- Department of Neurosurgery, University of Hamburg, Germany, Hamburg, Germany
| | - A von Deimling
- Department of Neuropathology, University of Heidelberg, Germany, Heidelberg, Germany
| | - A Unterberg
- Department of Neurosurgery, University of Heidelberg, Germany, Heidelberg, Germany
| | - M Simon
- Department of Neurosurgery, Bielefeld, Germany, Bielefeld, Germany
| |
Collapse
|
16
|
Hertler C, Roelcke U, Conen K, Huber F, Weiss T, Hofer S, Heese O, Westphal M, Roth P, Weller M, Eisele G. P01.108 Use of complementary and alternative medicine in glioma patients. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- C Hertler
- Department of Neurology, University Hospital Zurich, Zurich, Switzerl
| | - U Roelcke
- Brain Tumor Center, Kantonsspital Aarau, Aarau, Switzerl
| | - K Conen
- Department of Oncology, University Hospital Basel, Basel, Switzerl
- McMaster University Department of Family Medicine > Palliative and Supportive Care Clinic, Walker Family Cancer Centre, St. Catharines, ON, Canada
| | - F Huber
- Department of Neurology, Zurich, Switzerl
| | - T Weiss
- Department of Neurology, Zurich, Switzerl
| | - S Hofer
- Department of Oncology, University Hospital Zurich, Zurich, Switzerl
- Luzerner Kantonsspital, Luzern, Switzerl
| | - O Heese
- Department of Neurosurgery, Helios Kliniken Schwerin, Schwerin, Germany
| | - M Westphal
- Department of Neurosurgery, University Hospital Eppendorf, Hamburg, Germany
| | - P Roth
- Department of Neurology, University Hospital Zurich, Zurich, Switzerl
| | - M Weller
- Department of Neurology, University Hospital Zurich, Zurich, Switzerl
| | - G Eisele
- Department of Neurology, University Hospital Zurich, Zurich, Switzerl
| |
Collapse
|
17
|
Bähr O, Hentschel B, Hattingen E, Reusche M, Tatagiba M, Tonn J, Schnell O, Schackert G, Westphal M, Herrlinger U, Pietsch T, Reifenberger G, Weller M, Löffler M, Steinbach JP. OS2.1 Objective responses to chemotherapy in recurrent glioma do not predict better survival: A prospective analysis from the German Glioma Network. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- O Bähr
- University Hopsital Frankfurt, Frankfurt, Germany
| | | | | | - M Reusche
- University Leipzig, Leipzig, Germany
| | - M Tatagiba
- University Hopsital Tübingen, Tübingen, Germany
| | - J Tonn
- University Hopsital Munich (LMU), Munich, Germany
| | - O Schnell
- University Hopsital Freiburg, Freiburg, Germany
| | - G Schackert
- University Hopsital Dresden, Dresden, Germany
| | - M Westphal
- University Hopsital Hamburg (UKE), Hamburg, Germany
| | | | - T Pietsch
- University Hopsital Bonn, Bonn, Germany
| | | | - M Weller
- University Hopsital Zurich, Zurich, Germany
| | - M Löffler
- University Leipzig, Leipzig, Germany
| | | |
Collapse
|
18
|
Neidert MC, Kowalewski DJ, Wolpert F, Stevanovic S, Rammensee H, Lamszus K, Westphal M, Regli L, Weller M, Eisele G. P06.05 The natural HLA ligandome of glioblastoma stem-like cells: Antigen discovery for T-cell based immunotherapy. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.179] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Czorlich P, Sauvigny T, Ricklefs F, Abboud T, Nierhaus A, Vettorazzi E, Reuter DA, Regelsberger J, Westphal M, Schmidt NO. Impact of dexamethasone in patients with aneurysmal subarachnoid haemorrhage. Eur J Neurol 2017; 24:645-651. [DOI: 10.1111/ene.13265] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Accepted: 01/11/2017] [Indexed: 11/27/2022]
Affiliation(s)
- P. Czorlich
- Department of Neurosurgery; University Medical Center Hamburg − Eppendorf; Hamburg Germany
| | - T. Sauvigny
- Department of Neurosurgery; University Medical Center Hamburg − Eppendorf; Hamburg Germany
| | - F. Ricklefs
- Department of Neurosurgery; University Medical Center Hamburg − Eppendorf; Hamburg Germany
| | - T. Abboud
- Department of Neurosurgery; University Medical Center Hamburg − Eppendorf; Hamburg Germany
| | - A. Nierhaus
- Department of Intensive Care Medicine; University Medical Center Hamburg − Eppendorf; Hamburg Germany
| | - E. Vettorazzi
- Department of Medical Biometry and Epidemiology; University Medical Center Hamburg − Eppendorf; Hamburg Germany
| | - D. A. Reuter
- Department of Anaesthesiology; University Medical Center Hamburg − Eppendorf; Hamburg Germany
| | - J. Regelsberger
- Department of Neurosurgery; University Medical Center Hamburg − Eppendorf; Hamburg Germany
| | - M. Westphal
- Department of Neurosurgery; University Medical Center Hamburg − Eppendorf; Hamburg Germany
| | - N. O. Schmidt
- Department of Neurosurgery; University Medical Center Hamburg − Eppendorf; Hamburg Germany
| |
Collapse
|
20
|
Bothe M, Abele R, Baasner S, Faerber V, Harleman J, Meyer C, Topp H, Westphal M, Stover J. MON-LB286: Intravenous Glutamine Infusion is not Toxic in a Rat Model of Moderate Kidney Injury. Clin Nutr 2016. [DOI: 10.1016/s0261-5614(16)30920-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Dettmer S, Suhling H, Vogel-Claussen J, Westphal M, Haverich A, Welte T, Wacker F, Gottlieb J, Shin H. Veränderungen in der Computertomografie bei chronischer Allograft-Dysfunktion nach Lungentransplantation: Prädiktiver Wert für das weitere Fortschreiten der Erkrankung und das Überleben. ROFO-FORTSCHR RONTG 2016. [DOI: 10.1055/s-0036-1581813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
22
|
Morris RGM, Oertel W, Gaebel W, Goodwin GM, Little A, Montellano P, Westphal M, Nutt DJ, Di Luca M. Consensus Statement on European Brain Research: the need to expand brain research in Europe - 2015. Eur J Neurosci 2016; 44:1919-26. [PMID: 26990697 DOI: 10.1111/ejn.13236] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Accepted: 03/10/2016] [Indexed: 11/28/2022]
Affiliation(s)
- R G M Morris
- Federation of European Neuroscience Societies (FENS), Bruxelles, Belgium
| | - W Oertel
- European Academy of Neurology (EAN), Vienna, Austria
| | - W Gaebel
- European Psychiatric Association (EPA), Strasburg, France
| | - G M Goodwin
- European College of Neuropsychopharmacology (ECNP), Utrecht, The Netherlands
| | - A Little
- European Federation of Neurological Associations (EFNA), Bruxelles, Belgium
| | - P Montellano
- Global Alliance of Mental Illness Advocacy Networks-Europe (Gamian-Europe), Bruxelles, Belgium
| | - M Westphal
- European Association of Neurosurgical Societies (EANS), Gent, Belgium
| | - D J Nutt
- European Brain Council, Bruxelles, Belgium
| | - M Di Luca
- Federation of European Neuroscience Societies (FENS), Bruxelles, Belgium.,Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9-20133, Milan, Italy
| |
Collapse
|
23
|
Abstract
BACKGROUND Pituitary metastases are rare and commonly described in case reports or small case series. Due to its rarity this entity is not subject to standardized treatment guidelines, there is debate about typical initial symptoms that may lead to finding the correct diagnosis and information about the clinical course is also sparse. METHODS We have conducted a retrospective analysis of patients with pituitary metastases who were surgically treated via a transsphenoidal procedure at our institution between 2006 and 2014. Underlying primary disease, clinical and surgical course as well as adjuvant radiotherapy and follow-up data are presented. RESULTS 14 patients met the inclusion criteria (8 female, 6 male). Mean age was 61.5 years. Most patients became symptomatic with visual symptoms--both visual deterioration and/or diplopia (n = 13)--and anterior lobe insufficiency (n = 8). Surprisingly diabetes insipidus was only seen in three patients. All patients underwent transsphenoidal surgery initially, four patients had to undergo surgery for residual tumor or recurrence, two of them via a transcranial route. Breast cancer was the most common entity (n = 6), followed by prostate cancer (n = 3), nsclc (n = 2) and melanoma, thyroid cancer and renal cancer in one case each. Postoperative MRI showed gross total resection in four cases and residual disease in eight cases (subtotal resection, partial resection and biopsy), two patients files were incomplete regarding MRI-results. All patients underwent adjuvant radiotherapy. Survival after the initial diagnosis of cancer was 36 and 16 months after diagnosis of pituitary metastases. CONCLUSION Our results indicate that transsphenoidal surgery is a safe method to resect pituitary metastases and that the extend of resection does not have an influence on survival time. Our results also indicate that diabetes insipidus may not be the most common initial symptom of pituitary metastases and lack thereof should not lead to making a wrong diagnosis and delaying appropriate therapy.
Collapse
Affiliation(s)
- T Burkhardt
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
| | - M Henze
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
| | - L A Kluth
- Department of Urology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
| | - M Westphal
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
| | - N O Schmidt
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
| | - J Flitsch
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
| |
Collapse
|
24
|
Gulberti A, Moll CKE, Hamel W, Buhmann C, Koeppen JA, Boelmans K, Zittel S, Gerloff C, Westphal M, Schneider TR, Engel AK. Predictive timing functions of cortical beta oscillations are impaired in Parkinson's disease and influenced by L-DOPA and deep brain stimulation of the subthalamic nucleus. Neuroimage Clin 2015; 9:436-49. [PMID: 26594626 PMCID: PMC4596926 DOI: 10.1016/j.nicl.2015.09.013] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/23/2015] [Revised: 09/11/2015] [Accepted: 09/15/2015] [Indexed: 01/08/2023]
Abstract
Cortex-basal ganglia circuits participate in motor timing and temporal perception, and are important for the dynamic configuration of sensorimotor networks in response to exogenous demands. In Parkinson's disease (PD) patients, rhythmic auditory stimulation (RAS) induces motor performance benefits. Hitherto, little is known concerning contributions of the basal ganglia to sensory facilitation and cortical responses to RAS in PD. Therefore, we conducted an EEG study in 12 PD patients before and after surgery for subthalamic nucleus deep brain stimulation (STN-DBS) and in 12 age-matched controls. Here we investigated the effects of levodopa and STN-DBS on resting-state EEG and on the cortical-response profile to slow and fast RAS in a passive-listening paradigm focusing on beta-band oscillations, which are important for auditory–motor coupling. The beta-modulation profile to RAS in healthy participants was characterized by local peaks preceding and following auditory stimuli. In PD patients RAS failed to induce pre-stimulus beta increases. The absence of pre-stimulus beta-band modulation may contribute to impaired rhythm perception in PD. Moreover, post-stimulus beta-band responses were highly abnormal during fast RAS in PD patients. Treatment with levodopa and STN-DBS reinstated a post-stimulus beta-modulation profile similar to controls, while STN-DBS reduced beta-band power in the resting-state. The treatment-sensitivity of beta oscillations suggests that STN-DBS may specifically improve timekeeping functions of cortical beta oscillations during fast auditory pacing. High density EEG investigation in patients with PD before and after STN-DBS surgery Resting state EEG: altered spectral composition following STN-DBS Rhythmic auditory stimulation (RAS): absence of pre-stimulus beta activity in PD Fast RAS: normalization of beta (13–30 Hz) activities by L-DOPA and STN-DBS Altered beta modulation profile may contribute to timekeeping deficits in PD.
Collapse
Affiliation(s)
- A Gulberti
- Department of Neurophysiology and Pathophysiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - C K E Moll
- Department of Neurophysiology and Pathophysiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - W Hamel
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - C Buhmann
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - J A Koeppen
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - K Boelmans
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany ; Department of Neurology, University Hospital of Würzburg, Josef-Schneider-Strasse 11, Würzburg 97080, Germany
| | - S Zittel
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany ; Department of Paediatric and Adult Movement Disorders and Neuropsychiatry, Institute of Neurogenetics, University of Lübeck, Maria-Goeppert-Strasse 1, 23562 Lübeck, Germany
| | - C Gerloff
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - M Westphal
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - T R Schneider
- Department of Neurophysiology and Pathophysiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - A K Engel
- Department of Neurophysiology and Pathophysiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| |
Collapse
|
25
|
Bartels S, Bothe M, Honndorf S, Harleman J, Brito-de la Fuente E, Stover J, Westphal M. SUN-LB024: Omegaven® 10% Ameliorates Stroke Severity by Early Neuroprotection in a Transient Stroke Model in Mice. Clin Nutr 2015. [DOI: 10.1016/s0261-5614(15)30745-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
26
|
Gulberti A, Hamel W, Buhmann C, Boelmans K, Zittel S, Gerloff C, Westphal M, Engel A, Schneider T, Moll C. Subthalamic deep brain stimulation improves auditory sensory gating deficit in Parkinson’s disease. Clin Neurophysiol 2015; 126:565-74. [DOI: 10.1016/j.clinph.2014.06.046] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2014] [Revised: 06/18/2014] [Accepted: 06/27/2014] [Indexed: 01/01/2023]
|
27
|
Feuersenger A, Pradelli L, Aliano A, Baron JF, Westphal M. Short-term sedation of mechanically ventilated ICU patients with propofol, benzodiazepines, or dexmedetomidine: systematic review and meta-analysis on awakening and recovery times. Crit Care 2015. [PMCID: PMC4471840 DOI: 10.1186/cc14566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
28
|
Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot O, Balana C, Macdonald D, Westphal M, Hopkins K, Weller M, Bruey JM, Liu B, Verret W. ET-12 * PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou255.12] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Duhrsen L, Reitz M, Henze M, Sedlacik J, Riecken K, Fehse B, Westphal M, Schmidt NO. SC-07 * CYCLIC INTRANASAL APPLICATION OF NEURAL STEM CELL-MEDIATED ENZYM/PRODRUG THERAPY USING A NOVEL HSV-THYMIDINE KINASE VARIANT INHIBITS INTRACEREBRAL GLIOMA GROWTH AND IMPROVES SURVIVAL. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou275.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Tabatabai G, Felsberg J, Sabel M, Kaulich K, Hofer S, Westphal M, Weller M, Reifenberger G. AI-28 * RECURRENT GLIOBLASTOMAS AFTER TREATMENT WITH BEVACIZUMAB. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou238.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Riethdorf S, Westphal M, Mueller C, Holtschmidt J, Schulte A, Matschke J, Auer M, Speicher M, Lamszus K, Pantel K. BI-25 * CIRCULATING TUMOR CELLS IN GLIOBLASTOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou239.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Wick W, Hentschel B, Gramatzki D, Simon M, Schackert G, Tonn JC, Westphal M, Tatagiba M, Sabel M, Weyerbrock A, Pietsch T, Reifenberger G, Loeffler M, Weller M. BI-32 * RISK FACTOR ANALYSIS FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WHO DID NOT RECEIVE SALVAGE THERAPY. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou239.32] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Eisele G, Roelcke U, Conen K, Huber F, Weiss T, Hofer S, Heese O, Westphal M, Weller M. P18.01 * COMPLEMENTARY THERAPY USE IN A COHORT OF SWISS GLIOMA PATIENTS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Weller M, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J, Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, Sabel MC, Gramatzki D, Felsberg J, Hartmann C, Steinbach JP, Schlegel U, Wick W, Radlwimmer B, Pietsch T, Tonn JC, von Deimling A, Binder H, Loeffler M, Reifenberger G. MOLECULAR GENETIC DETERMINANTS OF LONG-TERM SURVIVAL WITH GLIOBLASTOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou209.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Schmidt NO, Duhrsen L, Reitz M, Henze M, Sedlacik J, Riecken K, Fehse B, Westphal M. REPEATED INTRANASAL APPLICATION OF NEURAL STEM CELL-MEDIATED ENZYM/PRODRUG THERAPY USING A NOVEL HSV-THYMIDINE KINASE VARIANT IMPROVES THERAPEUTIC EFFICIENCY IN AN INTRACRANIAL GLIOBLASTOMA MODEL. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou209.33] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Westphal M, Zamykal M, Martens T, Lamszus K. DIFFERENT MECHANISMS OF TUMOR GROWTH INHIBITION BY BLOCKADE OF IGF-IR IN U87-INDUCED AND STEM-LIKE CELL-INDUCED GLIOBLASTOMAS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou208.53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
37
|
Lamszus K, Kathagen A, Holz M, Schulte A, Westphal M. "GO OR GROW" - LINKS BETWEEN CELLULAR FUNCTION, GLUCOSE METABOLISM AND GLIOMA MICROENVIRONMENT. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou206.19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, Weller M, Tonn JC. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol 2013; 24:3117-23. [DOI: 10.1093/annonc/mdt388] [Citation(s) in RCA: 144] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Adachi K, Sasaki H, Nagahisa S, Yoshida K, Hattori N, Nishiyama Y, Kawase T, Hasegawa M, Abe M, Hirose Y, Alentorn A, Marie Y, Poggioli S, Alshehhi H, Boisselier B, Carpentier C, Mokhtari K, Capelle L, Figarella-Branger D, Hoang-Xuan K, Sanson M, Delattre JY, Idbaih A, Yust-Katz S, Anderson M, Olar A, Eterovic A, Ezzeddine N, Chen K, Zhao H, Fuller G, Aldape K, de Groot J, Andor N, Harness J, Lopez SG, Fung TL, Mewes HW, Petritsch C, Arivazhagan A, Somasundaram K, Thennarasu K, Pandey P, Anandh B, Santosh V, Chandramouli B, Hegde A, Kondaiah P, Rao M, Bell R, Kang R, Hong C, Song J, Costello J, Bell R, Nagarajan R, Zhang B, Diaz A, Wang T, Song J, Costello J, Bie L, Li Y, Li Y, Liu H, Luyo WFC, Carnero MH, Iruegas MEP, Morell AR, Figueiras MC, Lopez RL, Valverde CF, Chan AKY, Pang JCS, Chung NYF, Li KKW, Poon WS, Chan DTM, Wang Y, Ng HAK, Chaumeil M, Larson P, Yoshihara H, Vigneron D, Nelson S, Pieper R, Phillips J, Ronen S, Clark V, Omay ZE, Serin A, Gunel J, Omay B, Grady C, Youngblood M, Bilguvar K, Baehring J, Piepmeier J, Gutin P, Vortmeyer A, Brennan C, Pamir MN, Kilic T, Krischek B, Simon M, Yasuno K, Gunel M, Cohen AL, Sato M, Aldape KD, Mason C, Diefes K, Heathcock L, Abegglen L, Shrieve D, Couldwell W, Schiffman JD, Colman H, D'Alessandris QG, Cenci T, Martini M, Ricci-Vitiani L, De Maria R, Larocca LM, Pallini R, de Groot J, Theeler B, Aldape K, Lang F, Rao G, Gilbert M, Sulman E, Luthra R, Eterovic K, Chen K, Routbort M, Verhaak R, Mills G, Mendelsohn J, Meric-Bernstam F, Yung A, MacArthur K, Hahn S, Kao G, Lustig R, Alonso-Basanta M, Chandrasekaran S, Wileyto EP, Reyes E, Dorsey J, Fujii K, Kurozumi K, Ichikawa T, Onishi M, Ishida J, Shimazu Y, Kaur B, Chiocca EA, Date I, Geisenberger C, Mock A, Warta R, Schwager C, Hartmann C, von Deimling A, Abdollahi A, Herold-Mende C, Gevaert O, Achrol A, Gholamin S, Mitra S, Westbroek E, Loya J, Mitchell L, Chang S, Steinberg G, Plevritis S, Cheshier S, Gevaert O, Mitchell L, Achrol A, Xu J, Steinberg G, Cheshier S, Napel S, Zaharchuk G, Plevritis S, Gevaert O, Achrol A, Chang S, Harsh G, Steinberg G, Cheshier S, Plevritis S, Gutman D, Holder C, Colen R, Dunn W, Jain R, Cooper L, Hwang S, Flanders A, Brat D, Hayes J, Droop A, Thygesen H, Boissinot M, Westhead D, Short S, Lawler S, Bady P, Kurscheid S, Delorenzi M, Hegi ME, Crosby C, Faulkner C, Smye-Rumsby T, Kurian K, Williams M, Hopkins K, Faulkner C, Palmer A, Williams H, Wragg C, Haynes HR, Williams M, Hopkins K, Kurian KM, Haynes HR, Crosby C, Williams H, White P, Hopkins K, Williams M, Kurian KM, Ishida J, Kurozumi K, Ichikawa T, Onishi M, Fujii K, Shimazu Y, Oka T, Date I, Jalbert L, Elkhaled A, Phillips J, Chang S, Nelson S, Jensen R, Salzman K, Schabel M, Gillespie D, Mumert M, Johnson B, Mazor T, Hong C, Barnes M, Yamamoto S, Ueda H, Tatsuno K, Aihara K, Jalbert L, Nelson S, Bollen A, Hirst M, Marra M, Mukasa A, Saito N, Aburatani H, Berger M, Chang S, Taylor B, Costello J, Popov S, Mackay A, Ingram W, Burford A, Jury A, Vinci M, Jones C, Jones DTW, Hovestadt V, Picelli S, Wang W, Northcott PA, Kool M, Reifenberger G, Pietsch T, Sultan M, Lehrach H, Yaspo ML, Borkhardt A, Landgraf P, Eils R, Korshunov A, Zapatka M, Radlwimmer B, Pfister SM, Lichter P, Joy A, Smirnov I, Reiser M, Shapiro W, Mills G, Kim S, Feuerstein B, Jungk C, Mock A, Geisenberger C, Warta R, Friauf S, Unterberg A, Herold-Mende C, Juratli TA, McElroy J, Meng W, Huebner A, Geiger KD, Krex D, Schackert G, Chakravarti A, Lautenschlaeger T, Kim BY, Jiang W, Beiko J, Prabhu S, DeMonte F, Lang F, Gilbert M, Aldape K, Sawaya R, Cahill D, McCutcheon I, Lau C, Wang L, Terashima K, Yamaguchi S, Burstein M, Sun J, Suzuki T, Nishikawa R, Nakamura H, Natsume A, Terasaka S, Ng HK, Muzny D, Gibbs R, Wheeler D, Lautenschlaeger T, Juratli TA, McElroy J, Meng W, Huebner A, Geiger KD, Krex D, Schackert G, Chakravarti A, Zhang XQ, Sun S, Lam KF, Kiang KMY, Pu JKS, Ho ASW, Leung GKK, Loebel F, Curry WT, Barker FG, Lelic N, Chi AS, Cahill DP, Lu D, Yin J, Teo C, McDonald K, Madhankumar A, Weston C, Slagle-Webb B, Sheehan J, Patel A, Glantz M, Connor J, Maire C, Francis J, Zhang CZ, Jung J, Manzo V, Adalsteinsson V, Homer H, Blumenstiel B, Pedamallu CS, Nickerson E, Ligon A, Love C, Meyerson M, Ligon K, Mazor T, Johnson B, Hong C, Barnes M, Jalbert LE, Nelson SJ, Bollen AW, Smirnov IV, Song JS, Olshen AB, Berger MS, Chang SM, Taylor BS, Costello JF, Mehta S, Armstrong B, Peng S, Bapat A, Berens M, Melendez B, Mollejo M, Mur P, Hernandez-Iglesias T, Fiano C, Ruiz J, Rey JA, Mock A, Stadler V, Schulte A, Lamszus K, Schichor C, Westphal M, Tonn JC, Unterberg A, Herold-Mende C, Morozova O, Katzman S, Grifford M, Salama S, Haussler D, Nagarajan R, Zhang B, Johnson B, Bell R, Olshen A, Fouse S, Diaz A, Smirnov I, Kang R, Wang T, Costello J, Nakamizo S, Sasayama T, Tanaka H, Tanaka K, Mizukawa K, Yoshida M, Kohmura E, Northcott P, Hovestadt V, Jones D, Kool M, Korshunov A, Lichter P, Pfister S, Otani R, Mukasa A, Takayanagi S, Saito K, Tanaka S, Shin M, Saito N, Ozawa T, Riester M, Cheng YK, Huse J, Helmy K, Charles N, Squatrito M, Michor F, Holland E, Perrech M, Dreher L, Rohn G, Goldbrunner R, Timmer M, Pollo B, Palumbo V, Calatozzolo C, Patane M, Nunziata R, Farinotti M, Silvani A, Lodrini S, Finocchiaro G, Lopez E, Rioscovian A, Ruiz R, Siordia G, de Leon AP, Rostomily C, Rostomily R, Silbergeld D, Kolstoe D, Chamberlain M, Silber J, Roth P, Keller A, Hoheisel J, Codo P, Bauer A, Backes C, Leidinger P, Meese E, Thiel E, Korfel A, Weller M, Saito K, Mukasa A, Nagae G, Nagane M, Aihara K, Takayanagi S, Tanaka S, Aburatani H, Saito N, Salama S, Sanborn JZ, Grifford M, Brennan C, Mikkelsen T, Jhanwar S, Chin L, Haussler D, Sasayama T, Tanaka K, Nakamizo S, Nishihara M, Tanaka H, Mizukawa K, Kohmura E, Schliesser M, Grimm C, Weiss E, Claus R, Weichenhan D, Weiler M, Hielscher T, Sahm F, Wiestler B, Klein AC, Blaes J, Weller M, Plass C, Wick W, Stragliotto G, Rahbar A, Soderberg-Naucler C, Sulman E, Won M, Ezhilarasan R, Sun P, Blumenthal D, Vogelbaum M, Colman H, Jenkins R, Chakravarti A, Jeraj R, Brown P, Jaeckle K, Schiff D, Dignam J, Atkins J, Brachman D, Werner-Wasik M, Gilbert M, Mehta M, Aldape K, Terashima K, Shen J, Luan J, Yu A, Suzuki T, Nishikawa R, Matsutani M, Liang Y, Man TK, Lau C, Trister A, Tokita M, Mikheeva S, Mikheev A, Friend S, Rostomily R, van den Bent M, Erdem L, Gorlia T, Taphoorn M, Kros J, Wesseling P, Dubbink H, Ibdaih A, Sanson M, French P, van Thuijl H, Mazor T, Johnson B, Fouse S, Heimans J, Wesseling P, Ylstra B, Reijneveld J, Taylor B, Berger M, Chang S, Costello J, Prabowo A, van Thuijl H, Scheinin I, van Essen H, Spliet W, Ferrier C, van Rijen P, Veersema T, Thom M, Meeteren ASV, Reijneveld J, Ylstra B, Wesseling P, Aronica E, Kim H, Zheng S, Mikkelsen T, Brat DJ, Virk S, Amini S, Sougnez C, Chin L, Barnholtz-Sloan J, Verhaak RGW, Watts C, Sottoriva A, Spiteri I, Piccirillo S, Touloumis A, Collins P, Marioni J, Curtis C, Tavare S, Weiss E, Grimm C, Schliesser M, Hielscher T, Claus R, Sahm F, Wiestler B, Klein AC, Blaes J, Tews B, Weiler M, Weichenhan D, Hartmann C, Weller M, Plass C, Wick W, Yeung TPC, Al-Khazraji B, Morrison L, Hoffman L, Jackson D, Lee TY, Yartsev S, Bauman G, Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, Brennan CW, Yung WKA, Weinstein JN, Aldape KD, Sulman EP, Chen K, Koul D, Verhaak RGW. OMICS AND PROGNSTIC MARKERS. Neuro Oncol 2013; 15:iii136-iii155. [PMCID: PMC3823898 DOI: 10.1093/neuonc/not183] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2023] Open
|
40
|
Campian J, Gladstone D, Ambady P, Ye X, King K, Borrello I, Petrik S, Golightly M, Holdhoff M, Grossman S, Bhardwaj R, Chakravadhanula M, Ozols V, Georges J, Carlson E, Hampton C, Decker W, Chiba Y, Hashimoto N, Kagawa N, Hirayama R, Tsuboi A, Oji Y, Oka Y, Sugiyama H, Yoshimine T, Choi B, Gedeon P, Herndon J, Sanchez-Perez L, Mitchell D, Bigner D, Sampson J, Choi YA, Pandya H, Gibo DM, Debinski W, Cloughesy TF, Liau LM, Chiocca EA, Jolly DJ, Robbins JM, Ostertag D, Ibanez CE, Gruber HE, Kasahara N, Vogelbaum MA, Kesari S, Mikkelsen T, Kalkanis S, Landolfi J, Bloomfield S, Foltz G, Pertschuk D, Everson R, Jin R, Safaee M, Lisiero D, Odesa S, Liau L, Prins R, Gholamin S, Mitra SS, Richard CE, Achrol A, Kahn SA, Volkmer AK, Volkmer JP, Willingham S, Kong D, Shin JJ, Monje-Deisseroth M, Cho YJ, Weissman I, Cheshier SH, Kanemura Y, Sumida M, Yoshioka E, Yamamoto A, Kanematsu D, Takada A, Nonaka M, Nakajima S, Goto S, Kamigaki T, Takahara M, Maekawa R, Shofuda T, Moriuchi S, Yamasaki M, Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E, Lin Y, Wang Y, Qiu X, Jiang T, Lin Y, Wang Y, Jiang T, Zhang G, Wang J, Okada H, Butterfield L, Hamilton R, Drappatz J, Engh J, Amankulor N, Lively M, Chan M, Salazar A, Potter D, Shaw E, Lieberman F, Pandya H, Choi Y, Park J, Phuphanich S, Wheeler C, Rudnick J, Hu J, Mazer M, Wang H, Nuno M, Guevarra A, Sanchez C, Fan X, Ji J, Chu R, Bender J, Hawkins E, Black K, Yu J, Reap E, Archer G, Sanchez-Perez L, Norberg P, Schmittling R, Nair S, Cui X, Snyder D, Chandramohan V, Choi B, Kuan CT, Mitchell D, Bigner D, Yan H, Sampson J, Reardon D, Li G, Recht L, Fink K, Nabors L, Tran D, Desjardins A, Chandramouli N, Duic JP, Groves M, Clarke A, Hawthorne T, Green J, Yellin M, Sampson J, Rigakos G, Spyri O, Nomikos P, Stavridi F, Grossi I, Theodorakopoulou I, Assi A, Kouvatseas G, Papadopoulou E, Nasioulas G, Labropoulos S, Razis E, Rudnick J, Ravi A, Sanchez C, Tang DN, Hu J, Yu J, Sharma P, Black K, Sengupta S, Sampath P, Soto H, Erickson K, Malone C, Hickey M, Ha E, Young E, Ellingson B, Prins R, Liau L, Kruse C, Sul J, Hilf N, Kutscher S, Schoor O, Lindner J, Reinhardt C, Kreisl T, Iwamoto F, Fine H, Singh-Jasuja H, Teijeira L, Gil-Arnaiz I, Hernandez-Marin B, Martinez-Aguillo M, Sanchez SDLC, Viudez A, Hernandez-Garcia I, Lecumberri MJ, Grandez R, de Lascoiti AF, Garcia RV, Thomas A, Fisher J, Baron U, Olek S, Rhodes H, Gui J, Hampton T, Tafe L, Tsongalis G, Lefferts J, Wishart H, Kleen J, Miller M, Ernstoff M, Fadul C, Vlahovic G, Desjardins A, Peters K, Ranjan T, Herndon J, Friedman A, Friedman H, Bigner D, Archer G, Lally-Goss D, Sampson J, Wainwright D, Dey M, Chang A, Cheng Y, Han Y, Lesniak M, Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Yu J, Rudnick J, Hu J, Phuphanich S, Mazer M, Wang H, Xu M, Nuno M, Patil C, Chu R, Black K, Wheeler C. IMMUNOTHERAPY/BIOLOGICAL THERAPIES. Neuro Oncol 2013; 15:iii68-iii74. [PMCID: PMC3823893 DOI: 10.1093/neuonc/not178] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/09/2023] Open
|
41
|
Adams S, Teo C, McDonald K, Zinger A, Bustamante S, Lim CK, Braidy N, Brew BJ, Guillemin GJ, Agnihotri S, Burrell K, Singh S, Vartanian A, Wolf A, Lang F, Verhaak R, Hawkins C, Aldape K, Zadeh G, Chesnelong C, Chaumeil M, Blough MD, Al-Najjar M, Stechishin OD, Ronen S, Weiss S, Luchman HA, Cairncross JG, Fonkem E, Tobin R, Griffin J, Zuzek A, Rogers M, Giladi M, Wasserman Y, Urman N, Porat Y, Schneiderman R, Munster M, Weinberg U, Kirson E, Palti Y, Godlewski J, Bronisz A, Ansari K, Ogawa D, Nowicki MO, Chiocca EA, Kathagen A, Schulte A, Balcke G, Phillips H, Gunther H, Westphal M, Lamszus K, Makino K, Nakamura H, Hide TI, Yano S, Kuroda JI, Kuratsu JI, Fack F, Bonnel D, Hochart G, Navis AC, Wesseling P, Leenders WPJ, Stauber J, Niclou SP, Sahm F, Oezen I, Opitz C, Radlwimmer B, von Deimling A, Bode HB, Ahrendt T, Adams S, Guillemin G, Wick W, Platten M, Schonberg D, Lubelski D, Rich J, Vartanian A, Singh SK, Burrell K, Agnihotri S, Sabha N, Zadeh G. METABOLIC PATHWAYS. Neuro Oncol 2013. [DOI: 10.1093/neuonc/not205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Brognaro E, Chang S, Cha J, Choi K, Choi C, DePetro J, Binding C, Blough M, Kelly J, Lawn S, Chan J, Weiss S, Cairncross G, Eisenbeis A, Goldbrunner R, Timmer M, Gabrusiewicz K, Cortes-Santiago N, Fan X, Hossain MB, Kaminska B, Heimberger A, Rao G, Yung WKA, Marini F, Fueyo J, Gomez-Manzano C, Halle B, Marcusson E, Aaberg-Jessen C, Jensen SS, Meyer M, Schulz MK, Andersen C, Bjarne, Kristensen W, Hashizume R, Ihara Y, Ozawa T, Parsa A, Clarke J, Butowski N, Prados M, Perry A, McDermott M, James D, Jensen R, Gillespie D, Martens T, Zamykal M, Westphal M, Lamszus K, Monsalves E, Jalali S, Tateno T, Ezzat S, Zadeh G, Nedergaard MK, Kristoffersen K, Poulsen HS, Stockhausen MT, Lassen U, Kjaer A, Ohka F, Natsume A, Zong H, Liu C, Hatanaka A, Katsushima K, Shinjo K, Wakabayashi T, Kondo Y, Picotte K, Li L, Westerhuis B, Zhao H, Plotkin S, James M, Kalamarides M, Zhao WN, Kim J, Stemmer-Rachamimov A, Haggarty S, Gusella J, Ramesh V, Nunes F, Rao G, Doucette T, Yang Y, Fuller G, Rao A, Schmidt NO, Humke N, Meissner H, Mueller FJ, Westphal M, Schnell O, Jaehnert I, Albrecht V, Fu P, Tonn JC, Schichor C, Shackleford G, Swanson K, Shi XH, D'Apuzzo M, Gonzalez-Gomez I, Sposto R, Seeger R, Erdreich-Epstein A, Moats R, Sirianni RW, Heffernan JM, Overstreet DJ, Sleire L, Skeie BS, Netland IA, Heggdal J, Pedersen PH, Enger PO, Stiles C, Sun Y, Mehta S, Taylor C, Alberta J, Sundstrom T, Wendelbo I, Daphu I, Hodneland E, Lundervold A, Immervoll H, Skaftnesmo KO, Babic M, Jendelova P, Sykova E, Lund-Johansen M, Bjerkvig R, Thorsen F, Synowitz M, Ku MC, Wolf SA, Respondek D, Matyash V, Pohlmann A, Waiczies S, Waiczies H, Niendorf T, Glass R, Kettenmann H, Thompson N, Elder D, Hopkins K, Iyer V, Cohen N, Tavare J, Thorsen F, Fite B, Mahakian LM, Seo JW, Qin S, Harrison V, Sundstrom T, Harter PN, Johnson S, Ingham E, Caskey C, Meade T, Skaftnesmo KO, Ferrara KW, Tschida BR, Lowy AR, Marek CA, Ringstrom T, Beadnell TJ, Wiesner SM, Largaespada DA, Wenger C, Miranda PC, Mekonnen A, Salvador R, Basser P, Yoon J, Shin H, Choi K, Choi C. TUMOR MODELS (IN VIVO/IN VITRO). Neuro Oncol 2013. [DOI: 10.1093/neuonc/not193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Agarwal M, Nitta R, Dovat S, Li G, Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K, Kahn SA, Gholamin S, Junier MP, Chneiweiss H, Weissman I, Mitra S, Cheshier S, Avril T, Hamlat A, Le Reste PJ, Mosser J, Quillien V, Carrato C, Munoz-Marmol A, Serrano L, Pijuan L, Hostalot C, Villa SL, Ariza A, Etxaniz O, Balana C, Benveniste ET, Zheng Y, McFarland B, Drygin D, Bellis S, Bredel M, Lotsch D, Engelmaier C, Allerstorfer S, Grusch M, Pichler J, Weis S, Hainfellner J, Marosi C, Spiegl-Kreinecker S, Berger W, Bronisz A, Nowicki MO, Wang Y, Ansari K, Chiocca EA, Godlewski J, Brown K, Kwatra M, Brown K, Kwatra M, Bui T, Nitta R, Li G, Zhu S, Kozono D, Li J, Kushwaha D, Carter B, Chen C, Schulte J, Srikanth M, Das S, Zhang J, Lathia J, Yin L, Rich J, Olson E, Kessler J, Chenn A, Cherry A, Haas B, Lin YH, Ong SE, Stella N, Cifarelli CP, Griffin RJ, Cong D, Zhu W, Shi Y, Clark P, Kuo J, Hu S, Sun D, Bookland M, Darbinian N, Dey A, Robitaille M, Remke M, Faury D, Maier C, Malhotra A, Jabado N, Taylor M, Angers S, Kenney A, Ren X, Zhou H, Schur M, Baweja A, Singh M, Erdreich-Epstein A, Fu J, Koul D, Yao J, Saito N, Zheng S, Verhaak R, Lu Z, Yung WKA, Gomez G, Volinia S, Croce C, Brennan C, Cavenee W, Furnari F, Lopez SG, Qu D, Petritsch C, Gonzalez-Huarriz M, Aldave G, Ravi D, Rubio A, Diez-Valle R, Marigil M, Jauregi P, Vera B, Rocha AADL, Tejada-Solis S, Alonso MM, Gopal U, Isaacs J, Gruber-Olipitz M, Dabral S, Ramkissoon S, Kung A, Pak E, Chung J, Theisen M, Sun Y, Monrose V, Franchetti Y, Sun Y, Shulman D, Redjal N, Tabak B, Beroukhim R, Zhao J, Buonamici S, Ligon K, Kelleher J, Segal R, Haas B, Canton D, Diaz P, Scott J, Stella N, Hara K, Kageji T, Mizobuchi Y, Kitazato K, Okazaki T, Fujihara T, Nakajima K, Mure H, Kuwayama K, Hara T, Nagahiro S, Hill L, Botfield H, Hossain-Ibrahim K, Logan A, Cruickshank G, Liu Y, Gilbert M, Kyprianou N, Rangnekar V, Horbinski C, Hu Y, Vo C, Li Z, Ke C, Ru N, Hess KR, Linskey ME, Zhou YAH, Hu F, Vinnakota K, Wolf S, Kettenmann H, Jackson PJ, Larson JD, Beckmann DA, Moriarity BS, Largaespada DA, Jalali S, Agnihotri S, Singh S, Burrell K, Croul S, Zadeh G, Kang SH, Yu MO, Song NH, Park KJ, Chi SG, Chung YG, Kim SK, Kim JW, Kim JY, Kim JE, Choi SH, Kim TM, Lee SH, Kim SK, Park SH, Kim IH, Park CK, Jung HW, Koldobskiy M, Ahmed I, Ho G, Snowman A, Raabe E, Eberhart C, Snyder S, Agnihotri S, Gugel I, Remke M, Bornemann A, Pantazis G, Mack S, Shih D, Sabha N, Taylor M, Tatagiba M, Zadeh G, Krischek B, Schulte A, Liffers K, Kathagen A, Riethdorf S, Westphal M, Lamszus K, Lee JS, Xiao J, Patel P, Schade J, Wang J, Deneen B, Erdreich-Epstein A, Song HR, Leiss L, Gjerde C, Saed H, Rahman A, Lellahi M, Enger PO, Leung R, Gil O, Lei L, Canoll P, Sun S, Lee D, Ho ASW, Pu JKS, Zhang XQ, Lee NP, Dat PJR, Leung GKK, Loetsch D, Steiner E, Holzmann K, Spiegl-Kreinecker S, Pirker C, Hlavaty J, Petznek H, Hegedus B, Garay T, Mohr T, Sommergruber W, Grusch M, Berger W, Lukiw WJ, Jones BM, Zhao Y, Bhattacharjee S, Culicchia F, Magnus N, Garnier D, Meehan B, McGraw S, Hashemi M, Lee TH, Milsom C, Gerges N, Jabado N, Trasler J, Pawlinski R, Mackman N, Rak J, Maherally Z, Thorne A, An Q, Barbu E, Fillmore H, Pilkington G, Maherally Z, Tan SL, Tan S, An Q, Fillmore H, Pilkington G, Malhotra A, Choi S, Potts C, Ford DA, Nahle Z, Kenney AM, Matlaf L, Khan S, Zider A, Singer E, Cobbs C, Soroceanu L, McFarland BC, Hong SW, Rajbhandari R, Twitty GB, Gray GK, Yu H, Benveniste EN, Nozell SE, Minata M, Kim S, Mao P, Kaushal J, Nakano I, Mizowaki T, Sasayama T, Tanaka K, Mizukawa K, Nishihara M, Nakamizo S, Tanaka H, Kohta M, Hosoda K, Kohmura E, Moeckel S, Meyer K, Leukel P, Bogdahn U, Riehmenschneider MJ, Bosserhoff AK, Spang R, Hau P, Mukasa A, Watanabe A, Ogiwara H, Saito N, Aburatani H, Mukherjee J, Obha S, See W, Pieper R, Nakajima K, Hara K, Kageji T, Mizobuchi Y, Kitazato K, Fujihara T, Otsuka R, Kung D, Nagahiro S, Rajbhandari R, Sinha T, Meares G, Benveniste EN, Nozell S, Ott M, Litzenburger U, Rauschenbach K, Bunse L, Pusch S, Ochs K, Sahm F, Opitz C, von Deimling A, Wick W, Platten M, Peruzzi P, Chiocca EA, Godlewski J, Read R, Fenton T, Gomez G, Wykosky J, Vandenberg S, Babic I, Iwanami A, Yang H, Cavenee W, Mischel P, Furnari F, Thomas J, Ronellenfitsch MW, Thiepold AL, Harter PN, Mittelbronn M, Steinbach JP, Rybakova Y, Kalen A, Sarsour E, Goswami P, Silber J, Harinath G, Aldaz B, Fabius AWM, Turcan S, Chan TA, Huse JT, Sonabend AM, Bansal M, Guarnieri P, Lei L, Soderquist C, Leung R, Yun J, Kennedy B, Sisti J, Bruce S, Bruce R, Shakya R, Ludwig T, Rosenfeld S, Sims PA, Bruce JN, Califano A, Canoll P, Stockhausen MT, Kristoffersen K, Olsen LS, Poulsen HS, Stringer B, Day B, Barry G, Piper M, Jamieson P, Ensbey K, Bruce Z, Richards L, Boyd A, Sufit A, Burleson T, Le JP, Keating AK, Sundstrom T, Varughese JK, Harter P, Prestegarden L, Petersen K, Azuaje F, Tepper C, Ingham E, Even L, Johnson S, Skaftnesmo KO, Lund-Johansen M, Bjerkvig R, Ferrara K, Thorsen F, Takeshima H, Yamashita S, Yokogami K, Mizuguchi S, Nakamura H, Kuratsu J, Fukushima T, Morishita K, Tanaka H, Sasayama T, Tanaka K, Nakamizo S, Mizukawa K, Kohmura E, Tang Y, Vaka D, Chen S, Ponnuswami A, Cho YJ, Monje M, Tateishi K, Narita Y, Nakamura T, Cahill D, Kawahara N, Ichimura K, Tiemann K, Hedman H, Niclou SP, Timmer M, Tjiong R, Rohn G, Goldbrunner R, Timmer M, Tjiong R, Stavrinou P, Rohn G, Perrech M, Goldbrunner R, Tokita M, Mikheev S, Sellers D, Mikheev A, Kosai Y, Rostomily R, Tritschler I, Seystahl K, Schroeder JJ, Weller M, Wade A, Robinson AE, Phillips JJ, Gong Y, Ma Y, Cheng Z, Thompson R, Wang J, Fan QW, Cheng C, Gustafson W, Charron E, Zipper P, Wong R, Chen J, Lau J, Knobbe-Thosen C, Weller M, Jura N, Reifenberger G, Shokat K, Weiss W, Wu S, Fu J, Zheng S, Koul D, Yung WKA, Wykosky J, Hu J, Taylor T, Villa GR, Gomez G, Mischel PS, Gonias SL, Cavenee W, Furnari F, Yamashita D, Kondo T, Takahashi H, Inoue A, Kohno S, Harada H, Ohue S, Ohnishi T, Li P, Ng J, Yuelling L, Du F, Curran T, Yang ZJ, Zhu D, Castellino RC, Van Meir EG, Zhu W, Begum G, Wang Q, Clark P, Yang SS, Lin SH, Kahle K, Kuo J, Sun D. CELL BIOLOGY AND SIGNALING. Neuro Oncol 2013. [DOI: 10.1093/neuonc/not174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013; 81:1515-22. [DOI: 10.1212/wnl.0b013e3182a95680] [Citation(s) in RCA: 171] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
45
|
Gutenberg A, Bock HC, Brück W, Doerner L, Mehdorn HM, Roggendorf W, Westphal M, Felsberg J, Reifenberger G, Giese A. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. Br J Neurosurg 2013; 27:772-8. [PMID: 23662801 DOI: 10.3109/02688697.2013.791664] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The prognostic role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients treated with carmustine (BCNU) wafer implantation is unclear. Here, we report on a retrospective study of 47 patients with either newly diagnosed (30 patients) or recurrent (17 patients) glioblastoma (WHO grade IV) treated with BCNU (bis-chloroethylnitrosourea) wafers. Thirteen of the newly diagnosed patients received local BCNU and irradiation only (first-line BCNU), while 17 patients additionally received concomitant and adjuvant temozolomide (TMZ) radiochemotherapy (first-line BCNU + TMZ). Of the 17 patients treated for recurrent glioblastoma (second-line BCNU), 16 had received radiotherapy with concomitant and adjuvant TMZ as an initial treatment. Median overall survival (OS) did not significantly differ between 19 patients with MGMT promoter methylated tumors when compared to 28 patients with unmethylated tumors (18.9 vs 15.0 months; p = 0.1054). In the first-line BCNU + TMZ group, MGMT promoter methylation was associated with longer OS (21.0 vs 11.1 months, p = 0.0127), while no significant survival differences were detected in the other two subgroups. Progression-free survival did not significantly differ between patients with and without MGMT promoter methylated tumors in the entire patient cohort or any of the three subgroups. The first-line BCNU + TMZ group showed no significant difference in OS when compared to the first-line BCNU group (18.9 vs 14.7 months), but tended to have more therapy-related adverse effects (53% vs 24%, p = 0.105). In summary, MGMT promoter methylation showed a non-significant trend toward longer survival in our patient cohort. The combination of TMZ radiochemotherapy with local delivery of BCNU did not provide a significant survival benefit compared to local BCNU alone, but was associated with a higher rate of adverse effects. Owing to the small number of patients investigated, however, these findings would need to be corroborated in larger patient cohorts.
Collapse
Affiliation(s)
- A Gutenberg
- Department of Neurosurgery, Georg August University Göttingen , Göttingen , Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Gutenberg A, Lumenta CB, Braunsdorf WEK, Sabel M, Mehdorn HM, Westphal M, Giese A. The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neurooncol 2013; 113:163-74. [DOI: 10.1007/s11060-013-1110-x] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2012] [Accepted: 03/13/2013] [Indexed: 12/18/2022]
|
47
|
Rotermund R, Burkhardt T, Westphal M, Flitsch J. A current series of surgically treated hormone-active microadenomas treated at a single center. Exp Clin Endocrinol Diabetes 2013. [DOI: 10.1055/s-0033-1336622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
48
|
Burkhardt TR, Rotermund R, Kiefmann R, Westphal M, Flitsch J. PONV prophylaxis alters postoperative cortisol-measurement in transphenoidal pituitary surgery. Exp Clin Endocrinol Diabetes 2013. [DOI: 10.1055/s-0033-1336745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Phillips H, Armani M, Stavrou D, Ferrara N, Westphal M. Intense focal expression of vascular endothelial growth-factor messenger-RNA in human intracranial neoplasms - association with regions of necrosis. Int J Oncol 2012; 2:913-9. [PMID: 21573646 DOI: 10.3892/ijo.2.6.913] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
To examine the potential involvement of vascular endothelial growth factor (VEGF) in vascular changes which occur in human intracranial neoplasms, we examined a series of tumor specimens for expression of VEGF mRNA by in situ hybridization. VEGF was expressed at high levels by tumor cells in discrete regions in several of the tumors examined. The highest levels were detected in glioblastomas. The presence and location of foci of intense VEGF mRNA expression were, paradoxically well correlated with the presence of necrobiosis within the tumor mass. A less consistent association was observed between VEGF expression and either the degree of vascularization or endothelial cell proliferation. Since VEGF has been shown to induce tissue factor expression, VEGF itself may be involved in the pathogenesis of necrosis. Our findings provide evidence that VEGF mRNA is highly expressed in specific intracranial malignancies and suggest that VEGF plays a complex and multifunctional role in vascular biology.
Collapse
Affiliation(s)
- H Phillips
- UNIV HAMBURG,KRANKENHAUS EPPENDORF,DEPT NEUROL SURG,BRAIN TUMOR BIOL LAB,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY. UNIV HAMBURG,KRANKENHAUS EPPENDORF,INST NEUROPATHOL,W-2000 HAMBURG 20,GERMANY. GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080. GENENTECH INC,DEPT CARDIOVASC BIOL,S SAN FRANCISCO,CA 94080
| | | | | | | | | |
Collapse
|
50
|
Abstract
Growth factor/ligand interactions have been shown to play an important role in various malignancies. Expression of two differentially spliced forms of SCF was detected in 20 of 24 glioma cell lines by RT-PCR. Northern blot analysis revealed expression of the corresponding receptor, c-kit (11/24), as well as PDGF alpha-receptor (22/25 glioma cell lines), PDGF beta-receptor (22/25), TGF-alpha (13/24 ) and PDGF B/c-sis (7/16) expression. As determined by FACS analysis, expression of EGFR and p185HER2 was detected in 21 of 21 and 15 of 21 glioma cell lines, respectively. Four cell lines showed moderate EGFR overexpression (>90,000 receptors/cell) and in one cell line p 185HER2 expression exceeded EGFR levels. Loss of EGFR gene amplification during in vitro culturing was observed in 3 of 18 investigated cell lines by differential PCR. In summary, our work suggests the simultaneous activation of several different growth factor/receptor systems in human glioma cell lines.
Collapse
Affiliation(s)
- W Hamel
- UNIV HOSP EPPENDORF,DEPT NEUROL SURG,BRAIN TUMOUR BIOL LAB,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY. GENENTECH INC,DEPT DEV BIOL,SAN FRANCISCO,CA 94080
| | | | | |
Collapse
|